arrow
G

Guido Marcucci

City Of Hope National Medical Center
H指数:118
被引数:5.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

B-cell activating factor receptor expression in B-lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy

B细胞活化因子受体在B淋巴母细胞白血病中的表达:流式细胞术分析及其靶向治疗意义

2026-08-210
PRE
Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics

抑制ADSS2-mediated从头合成AMP使急性髓系白血病对BH3模拟物重新敏感

2026-06-260
PRE
Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia

BRAF突变在急性髓系白血病中的预后和治疗意义

Leukemia
IF13.4
2026-06-150
OAAI
Allosteric inhibition of RAN decreases miR-126 biogenesis in endothelial cells and controls acute myeloid leukemia growth

别构抑制RAN降低内皮细胞中miR-126的生物发生并控制急性髓系白血病生长

2026-04-140
OAAI
Novel NUTM1 Fusions in Relapsed Acute Myeloid Leukemia: Expanding the Genetic and Clinical Landscape

新型NUTM1融合在复发急性髓系白血病中的发现:扩展其遗传和临床图景

2025-12-020
OAAI
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis

异基因造血干细胞移植(allo-HCT)在采用氟达拉滨/美法仑(Fludarabine/Melphalan)预处理和他克莫司/西罗莫司(Tacrolimus/Sirolimus)移植物抗宿主病(GVHD)预防方案的急性髓系白血病(AML)中的长期生存结局。

2025-11-180
OAAI
Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis

异基因造血细胞移植治疗骨髓纤维化受者中中性粒细胞植入期间的肺部表现

2025-09-240
OA
Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplant in Patients With IDH-2 Mutated AML

在IDH-2突变急性髓系白血病异基因造血细胞移植后使用enasidenib维持治疗的试验

2025-09-190
PRE
The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden

细胞减灭术对高肿瘤负荷复发或难治性B-ALL患者博纳吐莫单抗疗效的影响

2025-09-090
PRE
Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia (vol 35, pg 2285, 2021)

细胞质DROSHA和MiR-155生物发生中非经典机制在FLT3-ITD急性髓系白血病中的作用(卷35,页2285,2021)

LEUKEMIA
IF13.4
2025-05-050
PRE
10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

10年随访研究:CALGB 10603/Ratify试验中,年龄18-60岁新诊断FLT3突变急性髓系白血病患者的米哚妥林与安慰剂联合强化化疗的比较

BLOOD
IF23.1
2024-11-050
PRE
Disrupting Mitochondrial Dynamics and Metabolism in Leukemic Stem Cells through Mitochondrial PCNA Inhibition: The Role of AOH1996

通过抑制线粒体PCNA破坏白血病干细胞中线粒体动力学和代谢:AOH1996的作用

BLOOD
IF23.1
2024-11-050
PRE
Combined CXCR-4 Inhibition with Novel Agent GPC-100 (burixafor) and Beta 2 Adrenergic Receptor Blockade Enhances Cytarabine Response for Acute Myeloid Leukemia Blasts on Stroma

联合使用CXCR-4抑制剂新型药物GPC-100(burixafor)和β2肾上腺素受体阻滞剂可增强急性髓系白血病细胞在基质中的阿糖胞苷反应。

BLOOD
IF23.1
2024-11-050
PRE
High HDAC8 Creates Targetable Vulnerabilities in Acute Myeloid Leukemia through Dysregulation of BRCA1-Related RNA Splicing Machinery and Defective DNA Damage Repair

高HDAC8通过调节BRCA1相关RNA剪接机制失调和DNA损伤修复缺陷,在急性髓系白血病中产生可靶向的脆弱性

BLOOD
IF23.1
2024-11-050
PRE